Hubei Goto Biopharm Co.,Ltd. (300966.SZ)
CNY 15.64
(0.51%)
CNY 15.64
(0.51%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 1.42 Billion CNY | 30.98% |
| 2022 | 1.08 Billion CNY | 183.99% |
| 2021 | 382.82 Million CNY | 44.69% |
| 2020 | 264.57 Million CNY | -21.36% |
| 2019 | 336.42 Million CNY | 62.67% |
| 2018 | 206.82 Million CNY | 13.09% |
| 2017 | 182.88 Million CNY | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q2 | 1.62 Billion CNY | 12.04% |
| 2024 Q3 | 1.66 Billion CNY | 2.44% |
| 2024 Q1 | 1.45 Billion CNY | 1.93% |
| 2023 Q3 | 1.21 Billion CNY | 9.32% |
| 2023 FY | 1.42 Billion CNY | 30.98% |
| 2023 Q4 | 1.42 Billion CNY | 17.65% |
| 2023 Q2 | 1.1 Billion CNY | 1.38% |
| 2023 Q1 | 1.09 Billion CNY | 0.45% |
| 2022 Q3 | 816.41 Million CNY | -4.75% |
| 2022 Q2 | 857.08 Million CNY | 81.08% |
| 2022 Q1 | 473.32 Million CNY | 23.64% |
| 2022 FY | 1.08 Billion CNY | 183.99% |
| 2022 Q4 | 1.08 Billion CNY | 33.16% |
| 2021 Q4 | 382.82 Million CNY | 43.07% |
| 2021 Q1 | 272.05 Million CNY | 2.82% |
| 2021 FY | 382.82 Million CNY | 44.69% |
| 2021 Q3 | 267.57 Million CNY | -0.91% |
| 2021 Q2 | 270.03 Million CNY | -0.74% |
| 2020 Q1 | - CNY | -100.0% |
| 2020 FY | 264.57 Million CNY | -21.36% |
| 2020 Q4 | 264.57 Million CNY | -11.33% |
| 2020 Q3 | 298.37 Million CNY | 5.04% |
| 2020 Q2 | 284.07 Million CNY | 0.0% |
| 2019 FY | 336.42 Million CNY | 62.67% |
| 2019 Q4 | 336.42 Million CNY | 0.0% |
| 2018 FY | 206.82 Million CNY | 13.09% |
| 2017 FY | 182.88 Million CNY | 0.0% |